MPLT

+ Watchlist + Portfolio

MapLight Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $12.15
52-Week Range: $9.10 – $40.43
Market Cap: $520.82M
P/E (TTM): —
EPS (TTM): -19.96
Dividend Yield: —

Advanced Metrics

Price/Book: 1.46
PEG Ratio: —
Return on Equity: -111.55%
Return on Assets: -67.11%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 16.52
Debt/Equity: 0.01
Total Debt: $1.99M
Free Cash Flow: $-95.21M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $260.75M

MPLT Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	—	—	$0.00
Research & Development	—	—	$138.35M
Selling, General & Admin	—	—	$30.73M
Operating Expenses	—	—	$169.08M
Operating Income	—	—	-$169.08M
EBITDA	—	—	-$168.50M
Pretax Income	—	—	-$161.15M
Net Income	—	—	-$161.15M
Diluted EPS	—	-2.96	-18.56
Diluted Shares	—	26.18M	8.68M

MPLT Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	—	$0.00	$0.00	$0.00
Research & Development	$20.71M	$19.79M	$27.09M	$64.62M	$53.68M
Selling, General & Admin	$2.06M	—	$4.40M	$18.75M	$10.82M
Operating Expenses	$22.78M	$23.54M	$31.50M	$83.38M	$64.50M
Operating Income	-$22.78M	-$23.54M	-$31.50M	-$83.38M	-$64.50M
EBITDA	-$22.58M	-$23.38M	-$31.36M	-$83.24M	-$64.34M
Pretax Income	-$21.23M	-$22.34M	-$29.42M	-$79.55M	-$60.67M
Net Income	-$21.23M	-$22.34M	-$29.42M	-$79.55M	-$60.67M
Diluted EPS	—	-0.54	-0.71	-2.47	-1.34
Diluted Shares	—	—	41.43M	32.15M	45.21M

MPLT Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	—	—	$64.15M	$46.73M	$55.71M
Current Assets	—	—	$245.31M	$324.67M	$327.23M
Total Assets	—	—	$257.22M	$479.51M	$418.79M
Current Liabilities	—	—	$18.56M	$16.23M	$14.28M
Total Debt	—	—	$6.01M	$5.80M	$5.59M
Total Liabilities	$18.57M	$20.36M	$23.71M	$21.14M	$18.95M
Retained Earnings	—	—	-$280.97M	-$360.52M	-$421.19M
Shareholders' Equity	$93.00M	$63.76M	$233.52M	$458.37M	$399.83M
Working Capital	—	—	$226.74M	$308.44M	$312.94M

MPLT Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$21.49M	—	-$31.79M	-$46.83M	-$51.18M
Capital Expenditure	-$106.00K	—	-$31.00K	-$376.00K	-$24.00K
Free Cash Flow	-$21.59M	—	-$31.82M	-$47.20M	-$51.20M
Depreciation & Amortisation	$194.00K	—	$136.00K	$140.00K	$162.00K
Stock-Based Compensation	$214.00K	—	$125.00K	$35.52M	$9.64M
Investing Cash Flow	$32.39M	—	-$135.59M	-$242.55M	$67.01M
Financing Cash Flow	$5.00K	—	$198.06M	$271.96M	-$6.85M
Net Change in Cash	$10.91M	—	$30.68M	-$17.42M	$8.98M

Market Snapshot

About

Clinical-stage biopharmaceutical company developing novel therapies for neuroscience and rare diseases. Pipeline targets mechanisms including cellular plasticity and neurodegeneration. Focus on conditions with high unmet medical need and limited treatment options.